Status:

RECRUITING

Concentration Impact Nicotine Salt

Lead Sponsor:

Insel Gruppe AG, University Hospital Bern

Collaborating Sponsors:

Swiss National Science Foundation

Conditions:

Smoking Cessation

Vaping

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Double-blind (for the two active arms), randomized, three-arm (two active and one control) clinical trial investigating factors (e.g. nicotine concentration) influencing the success of smoking cessati...

Detailed Description

At the clinic screening visit demographics, smoking (including the Fagerström Test for Cigarette Dependence (FTCD) Questionnaire) and medical history, concomitant medication, vital signs, body mass in...

Eligibility Criteria

Inclusion

  • Adult (≥ 18 years old) smokers (at least 5 TC per day for at least 12 months)
  • Motivated to quit smoking as evidenced by signing the informed consent form at trial enrolment specifying that a target quit date will be set
  • Exhaled CO ≥ 10 ppm or saliva cotinine of \> 30 ng/ml (in case of borderline CO measurement of 6-10 ppm) at screening
  • Willing to participate in the trial even if allocated to the control group
  • Ability to communicate well with the investigator and to understand and comply with the requirements of the study
  • Signed informed consent form

Exclusion

  • Known hypersensitivity/allergy to a content of the e-liquid
  • Pregnancy or breast feeding
  • Intention to become pregnant during the course of the study
  • Current regular use of EC or tobacco heating systems
  • Use of NRT, varenicline, or bupropion in the month prior to the screening visit
  • People who smoke tobacco combined with marijuana and do not currently want to quit marijuana use
  • Participation in an interventional trial within 30 days prior to the screening visit
  • Legal incapacity or limited legal capacity at screening
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

Key Trial Info

Start Date :

January 30 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

312 Patients enrolled

Trial Details

Trial ID

NCT04725656

Start Date

January 30 2024

End Date

December 31 2025

Last Update

March 28 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Inselspital

Bern, Switzerland

Concentration Impact Nicotine Salt | DecenTrialz